MarketVue® Report
Alopecia Areata (AA) (U.S.), 2022

Syndicated market assessment report driven by primary market research

REPORT STORE

Alopecia Areata (AA) (U.S.), January 2022

DOWNLOAD SAMPLE REPORT
DOWNLOAD REPORT BROCHURE
The MarketVue®: Alopecia Areata market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
 
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
 
Topics covered in this report:
  • Disease overview: Review the disease pathophysiology and potential druggable targets
  • Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
  • Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
  • Unmet needs: Identify opportunities to address treatment or disease management gaps
  • Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
  • Value and access: Gain insights into the drug pricing landscape and payer controls within the disease market or analogous markets
 
Methodology:
Research for the MarketVue®: Alopecia Areata report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research.
 
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
 
Key companies mentioned:
  • Eli Lilly
  • Incyte
  • Pfizer
  • Concert Pharmaceuticals
  • AbbVie
  • Suzhou Zelgen Biopharmaceuticals
  • Legacy Healthcare
  • Throne Biotechnologies
  • Arena Pharmaceuticals
  • Reistone Biopharma
  • Bioniz Therapeutics / Equillium
 
Key drugs mentioned:
  • Injectable and topical steroids
  • Minoxidil (Rogaine)
  • Methotrexate (Trexall, Rheumatrex)
  • Diphencyprone (DPCP)
  • Tacrolimus (Prograf , Protopic)
  • Baricitinib (Olumiant)
  • Tofacitinib (Xeljanz)
  • Dupilumab (Dupixent)
  • Ruxolitinib (Jakafi, Opzelura)
  • Adalimumab (Humira)
  • Upadacitinib (Rinvoq
  • Ritlecitinib (Litfulo)
  • Coacillium
  • Stem Cell Educator (SCE) therapy
  • Etrasimod (Velsipity)
  • SHR0302
  • BNZ-1
  • Jaktinib
1. DISEASE OVERVIEW
An autoimmune condition that causes hair to fall out
Table 1.1. Types of alopecia areata
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. G6 prevalent cases of alopecia areata by region
Table 2.1 Prevalent alopecia areata population in the US and EU5
Patchy alopecia areata is the predominate form of the disease
Figure 2.2. Alopecia areata population by severity
Figure 2.3. Dermatologist-reported key population dynamics in alopecia areata
3. CURRENT TREATMENT
Overview
Figure 3.1. Treatment goals for alopecia areata
Figure 3.2. U.S. dermatologist alopecia areata patient load
Standard of care
Figure 3.3. U.S. Dermatologist-reported patient share of current treatments in alopecia areata
Table 3.1. Upsides and downsides of currently available treatment options
Figure 3.4. Treatment algorithm for the management of alopecia areata
In their own words: Dermatologists’ insights on alopecia areata treatments
Dermatologists hope JAK inhibitors will become the first-approved class for alopecia area
Table 3.2. Must-know alopecia areata treatment dynamics for now and the future
The burden of disease in alopecia areata is not just cosmetic but also psychosocial in nature
Figure 3.5. Dermatologists’ rating of the impact of alopecia areata on patients
In their own words: More of dermatologists’ thoughts on the burden of alopecia areata
Dermatologists are excited about JAK inhibitors but the pipeline is weak for other MOAs
Figure 3.6. Timeline of alopecia areata market evolution
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in alopecia areata
Figure 4.2. Dermatologist-reported unmet needs in alopecia areata
In their own words: Dermatologists opinion on top unmet needs for alopecia areata
Figure 4.3. Percentage of alopecia areata patients in which U.S. dermatologists are dissatisfied with current therapies
Figure 4.4. U.S. dermatologists view on the need for new treatments in dermatology conditions
Alopecia areata patient insights on unmet needs
Figure 4.5. Key takeaways from the FDA’s “Voice of the Patient” on alopecia areata
5. PIPELINE ANALYSIS
Clinical trials for alopecia areata are focused on promoting scalp hair regrowth
Figure 5.1. Number of emerging therapies addressing unmet needs in alopecia areata
Figure 5.2. Percentage of dermatologists rating target as “promising” for treating alopecia areata
Dermatologists are cautious but not deterred over FDA warning for JAK inhibitors
Summary of clinical-stage emerging alopecia areata therapies
Figure 5.3. Phase 3 results for Eli Lilly/Incyte’s baricitnib in severe alopecia areata
Table 5.1. Emerging alopecia areata therapies
6. VALUE & ACCESS
Overview
Table 6.1. Alopecia areata current therapy pricing, U.S.
Reimbursement for alopecia areata drugs will be met with hurdles
Table 6.2. ICD-10 diagnosis codes for alopecia areata
Figure 6.1. Reimbursement and access considerations for emerging therapies in alopecia areata
Figure 6.1. Alopecia areata patients by insurance type in the U.S.
Figure 6.2. Alopecia areata patients by insurance type in the U.S.
Figure 6.3. Key considerations for building a market access strategy in alopecia areata
7. METHODOLOGY
Primary market research approach
Epidemiology methodology
Disease definition
Prevalence estimates
What is the difference between purchasing a published report and requesting a new report?

Published reports have been pre-produced on the specified date and can be delivered immediately. If you prefer to refresh an existing report or request an entirely new disease, REACH can create and deliver any new report within 15 business days.

How does REACH produce new primary market research reports in 15 business days?

By deploying our senior team to each of our reports, we can begin insight generation on day 1. The REACH team also recruits Key Opinion Leaders from our internal panel rather than outsourcing recruitment which enables us to quickly begin primary market research interviews.

Who writes REACH reports?

Each REACH report is produced by one of our senior US-based team members with 10+ years of experience in life sciences market research. We are deeply committed to ensuring REACH reports are high quality and strategic to enable informed decision-making for our clients.

Does REACH cover both rare and non-rare diseases?

REACH specializes in covering diseases and subpopulations that are not addressed by traditional market research reports. As such, we focus on rare diseases and niche subpopulations of more common conditions (e.g., Dupixent-refractory atopic dermatitis). Our flexible model enables in-depth assessments across all disease types, allowing us to support research for non-rare conditions as well.

Can I meet with the team to discuss the report?

Contact us to set up a call directly with the analyst who has written the report to answer any questions and discuss the key takeaways.

Published Report

Download immediately.


New Report

Updated upon purchase. Delivered in 15 days.


Undecided about purchasing this report?

» Inquire before buying

Reach out to learn more about report bundle discounts

Reach out to our team to learn more about our capabilities and view sample reports.

Contact us